Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AstraZeneca PLC
Pink Sheet infographic breaks down the mix of patient advocacy groups, individual patients and clinicians offering input to CMS on the first 10 drugs facing Medicare price negotiation.
Inavolisib meets statistical significance for progression-free survival in HR+/HER2- advanced breast cancer with a PI3KCα mutation, which could set up competition with Piqray, Ibrance and Kisqali.
Several crucial trial readouts in diabetes and obesity will come this year and next, and the stakes are high.
With the only FDA-approved treatment off the market, the FDA is looking for ideas for development of new preterm birth treatments.
- Other Names / Subsidiaries
- Alexion Pharmaceuticals Inc.
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Cellective Therapeutics, Inc.
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Neogene Therapeutics, Inc.
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- TeneoTwo, Inc.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.